The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy
Alexandre Hirayama
• 2 Jul 2019
Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the analysis of the clinical determinants for the safety and effiacy of camidanlumab tesirine (Cami-T; ADCT-301) for relapsed/refractory classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
